NPs) also demonstrated superior efficacy of multilamellar tumor specific RNA-NPs, relative to anionic LPX and RNA LPX, and demonstrated the ability to systemically activate DCs, induce antigen specific immunity, and elicit anti-tumor efficacy *in vivo*. The administration of multilamellar RNA NPs to diseased animals (e.g., tumor bearing mice) also led to increased survival of these animals. Without being bound to a particular theory, the multilamellar RNA nanoparticles of the present disclosure are capable of safely and effectively inducing immunity against SARS-CoV-2.

[0006a] In one aspect, the present disclosure provides a nanoparticle comprising a positively-charged surface and an interior comprising (i) a core and (ii) at least two nucleic acid layers, wherein each nucleic acid layer is positioned between a cationic lipid bilayer, wherein the nanoparticle comprises RNA molecules encoding a SARS-CoV-2 protein.

[0006b] In another aspect, the present disclosure provides a method of making a nanoparticle comprising a positively-charged surface and an interior comprising (i) a core and (ii) at least two nucleic acid layers, wherein each nucleic acid layer is positioned between a cationic lipid bilayer, wherein the nanoparticle comprises RNA molecules encoding a SARS-CoV-2 protein, said method comprising: (A) mixing nucleic acid molecules encoding a SARS-CoV-2 protein and liposomes at a nucleic acid: liposome ratio of about 1 to about 5 to about 1 to about 20, optionally, about 1 to about 15, to obtain a nucleic acid-coated liposomes, wherein the liposomes are made by a process of making liposomes comprising drying a lipid mixture comprising a cationic lipid and an organic solvent by evaporating the organic solvent under a vacuum; and (B) mixing the nucleic acid-coated liposomes with a surplus amount of liposomes.

[0006c] In another aspect, the present disclosure provides a cell comprising a nanoparticle as described in the disclosure.

[0006d] In another aspect, the present disclosure provides a pharmaceutical composition comprising a plurality of nanoparticles according to the disclosure and a pharmaceutically acceptable carrier, diluent, or excipient.

[0006e] In another aspect, the present disclosure provides a use of the pharmaceutical composition of the disclosure in the manufacture of a medicament for treating SARS-CoV-2 infection in a subject, wherein the medicament is to be administered to a subject, and wherein the administration induces an immune response against a SARS-CoV-2 virus in the subject.

[0006f] In another aspect, the present disclosure provides a use of the pharmaceutical composition of the disclosure in the manufacture of a medicament for preventing SARS-CoV-2 infection in a subject, wherein the medicament induces an immune response against SAR-CoV-2 in a subject, and wherein the medicament is to be administered to a subject.

[0007] The present disclosure provides a nanoparticle comprising a positively-charged surface and an interior comprising (i) a core and (ii) at least two nucleic acid layers, wherein each nucleic acid layer is positioned between a cationic lipid bilayer, wherein the nanoparticle comprises RNA molecules encoding a SARS-CoV-2

protein, optionally, a SARS-CoV-2 Spike (S) protein. In exemplary ~~embodiment~~examples, the nanoparticle comprises at least three nucleic acid layers, each of which is positioned between a cationic lipid bilayer. In exemplary ~~aspect~~examples, the nanoparticle comprises at least four or five or more nucleic acid layers, each of which is positioned between a cationic lipid bilayer. In various ~~aspect~~examples, the outermost layer of the nanoparticle comprises a cationic lipid bilayer. In various instances, the surface comprises a plurality of hydrophilic moieties of the cationic lipid of the cationic lipid bilayer. In exemplary ~~aspect~~examples, the core comprises a cationic lipid bilayer. Optionally, the core comprises less than about 0.5 wt% nucleic acid. The diameter of the nanoparticle, in various ~~aspect~~examples, is about 50 nm to about 250 nm in diameter, optionally, about 70 nm to about 200 nm in diameter. In exemplary instances, the nanoparticle is characterized by a zeta potential of about +40 mV to about +60 mV, optionally, about +45 mV to about +55 mV. The nanoparticle in various instances, has a zeta potential of about 50 mV. In some ~~aspect~~examples, the nucleic acid molecules are present at a nucleic acid molecule:cationic lipid ratio of about 1 to about 5 to about 1 to about 25, such as about 1 to about 5 to about 1 to about 20, optionally, about 1 to about 15, about 1 to about 10, or about 1 to about 7.5. In various ~~aspect~~examples, the nucleic acid molecules are RNA molecules, optionally, messenger RNA (mRNA).

[0008] In cancer-related ~~aspect~~examples of the technology described herein, the mRNA is *in vitro* transcribed mRNA wherein the *in vitro* transcription template is cDNA made from RNA extracted from a sample.

[0009] The present disclosure also provides a method of making a nanoparticle comprising a positively-charged surface and an interior comprising (i) a core and (ii) at least two nucleic acid layers, wherein each nucleic acid layer is positioned between a cationic lipid bilayer, wherein the nanoparticle comprises RNA molecules encoding a SARS-CoV-2 protein, optionally, a SARS-CoV-2 Spike (S) protein, said method comprising: (A) mixing nucleic acid molecules and liposomes at a RNA: liposome ratio of 1 to about 5 to about 1 to about 25, such as about 1 to about 5 to about 1 to about 20, optionally, about 1 to about 15, about 1 to about 10, or about 1 to about 7.5, to obtain a RNA-coated liposomes, wherein the liposomes are made by a process of making liposomes comprising drying a lipid mixture comprising a cationic lipid and an organic solvent by evaporating the organic solvent under a vacuum; and (B) mixing the RNA-coated liposomes with a surplus amount of liposomes. In exemplary ~~aspect~~examples, the lipid mixture comprises the cationic lipid and the organic solvent at a ratio of about 40 mg cationic lipid per mL organic solvent to about 60 mg cationic lipid per mL organic

solvent, optionally, at a ratio of about 50 mg cationic lipid per mL organic solvent. In various instances, the process of making liposomes further comprises rehydrating the lipid mixture with a rehydration solution to form a rehydrated lipid mixture and then agitating, resting, and sizing the rehydrated lipid mixture. Optionally, sizing the rehydrated lipid mixture comprises sonicating, extruding and/or filtering the rehydrated lipid mixture. In exemplary ~~aspect~~examples, the RNA molecules are mRNA encoding SARS-CoV-2 protein, optionally mRNA encoding the SARS-CoV-2 S protein.

[0010] Further provided herein are nanoparticles made by the presently disclosed method of making a nanoparticle. Additionally provided herein is a cell comprising a nanoparticle of the present disclosure. Optionally, the cell is an antigen presenting cell (APC), e.g., a dendritic cell (DC). The present disclosure also provides a population of cells, wherein at least 50% of the population are cells according to the present disclosure. Pharmaceutical compositions comprising such cells comprising a nanoparticle of the present disclosure, or a population of such cells, are provided herein. The cells, or population of cells, in various ~~aspect~~examples, are suitable for administration to a subject.

[0011] The present disclosure provides a pharmaceutical composition comprising a plurality of nanoparticles according to the present disclosure and a pharmaceutically acceptable carrier, diluent, or excipient. In various ~~aspect~~examples, the composition comprises about 10^{10} nanoparticles per mL to about 10^{15} nanoparticles per mL, optionally about 10^{12} nanoparticles ± 10% per mL.

[0012] A method of inducing or increasing an immune response against a SARS-CoV-2 virus in a subject is provided by the present disclosure. In exemplary ~~embodiment~~examples, the method comprises administering to the subject the pharmaceutical composition of the present disclosure. In exemplary ~~aspect~~examples, the nucleic acid molecules are mRNA. Optionally, the composition is systemically administered to the subject. For example, the composition is administered intravenously. In various ~~aspect~~examples, the pharmaceutical composition is administered in an amount which is effective to activate dendritic cells (DCs) in the subject. In various instances, the immune response is a T cell-mediated immune response. Optionally, the T cell-mediated immune response comprises activity by tumor infiltrating lymphocytes (TILs).

[0013] The present disclosure also provides a method of delivering RNA molecules to lungs of a subject. The present disclosure also provides a method of delivering RNA molecules to a lymph node and/or a reticuloendothelial organ (e.g., spleen or liver). In exemplary ~~embodiment~~examples, the method comprises administering to the subject a presently disclosed pharmaceutical composition.

[0014] A method of treating a subject with a disease or disorder is furthermore provided herein. In exemplary ~~embodiment~~examples, the method comprises administering to the subject a pharmaceutical composition of the present disclosure in an amount effective to treat the disease or disorder in the subject. In various instances, the subject has COVID-19 or is at risk of infection with SARS-CoV-2.

[0015] Additional ~~embodiments and aspect~~aspects and examples of the presently disclosed pharmaceutical compositions and methods are provided below.

WHAT IS CLAIMED:

1. A nanoparticle comprising a positively-charged surface and an interior comprising (i) a core and (ii) at least two nucleic acid layers, wherein each nucleic acid layer is positioned between a cationic lipid bilayer, wherein the nanoparticle comprises RNA molecules encoding a SARS-CoV-2 protein.

2. The nanoparticle of claim 1, comprising at least three, at least four, or at least five nucleic acid layers, each of which is positioned between a cationic lipid bilayer.

~~3. The nanoparticle of claim 2, comprising at least four nucleic acid layers, each of which is positioned between a cationic lipid bilayer.~~

~~4. The nanoparticle of claim 3, comprising five or more nucleic acid layers, each of which is positioned between a cationic lipid bilayer.~~

~~5.~~3. The nanoparticle of any one of claims 1-~~4~~2, wherein the outermost layer of the nanoparticle comprises a cationic lipid bilayer.

~~6. The nanoparticle of any one of claims 1-5, wherein the surface comprises a plurality of hydrophilic moieties of the cationic lipid of the cationic lipid bilayer.~~

~~7.~~4. The nanoparticle of any one of claims 1-~~6~~3, wherein the core comprises a cationic lipid bilayer.

~~8.~~5. The nanoparticle of any one of claims 1-~~7~~4, wherein the core comprises less than about 0.5 wt% nucleic acid.

~~9.~~6. The nanoparticle of any one of claims 1-~~8~~5, wherein the diameter of the nanoparticle is about 50 nm to about ~~250~~ 500 nm in diameter, optionally, about 70 nm to about 200 nm in diameter.

~~10.~~7. The nanoparticle of any one of claims 1-~~9~~6, comprising a zeta potential of about 40 mV to about 60 mV, optionally, about 45 mV to about 55 mV.

~~11.~~8. The nanoparticle of claim ~~10~~7, comprising a zeta potential of about 50 mV.

~~12.~~9. The nanoparticle of any one of claims 1-~~11~~8, comprising nucleic acid molecules and cationic lipid at a ratio of about 1 to about 5 to about 1 to about 20, optionally, about 1 to about 15 or about 1 to about 7.5.

~~13.~~10. The nanoparticle of any one of claims 1-~~12~~9, wherein the cationic lipid is DOTAP or DOTMA.

~~14. The nanoparticle of any one of claims 1-13, wherein the nucleic acid molecules are RNA molecules.~~

~~15. The nanoparticle of claim 14, wherein the RNA molecules are mRNA.~~

~~16.~~11. The nanoparticle of any one of claims 1-~~15~~10, wherein the mRNAs encode a SARS-CoV-2 Spike (S) protein or a fragment thereof.

~~17.~~12. The nanoparticle of claim ~~16~~11, wherein the S protein comprises the amino acid sequence set forth in Figure 20.

~~18.~~13. The nanoparticle of any one of claims 1-~~17~~13, wherein the mRNAs encode a SARS-CoV-2 membrane protein, envelope protein, or a nucleocapsid protein.

~~19. The nanoparticle of any one of claims 1-18, wherein the liposomes are prepared by mixing the nucleic acid molecules and the cationic lipid at a RNA: cationic lipid ratio of about 1 to about 5 to about 1 to about 20, optionally, about 1 to about 15.~~

~~20.~~14. A method of making a nanoparticle comprising a positively-charged surface and an interior comprising (i) a core and (ii) at least two nucleic acid layers, wherein each nucleic acid layer is positioned between a cationic lipid bilayer, wherein the nanoparticle comprises RNA molecules encoding a SARS-CoV-2 protein, said method comprising:

(A) mixing nucleic acid molecules encoding a SARS-CoV-2 protein and liposomes at a nucleic acid: liposome ratio of about 1 to about 5 to about 1 to about 20, optionally, about 1 to about 15, to obtain a nucleic acid-coated liposomes, wherein the liposomes are made by a process of making liposomes comprising drying a lipid mixture comprising a cationic lipid and an organic solvent by evaporating the organic solvent under a vacuum; and

(B) mixing the nucleic acid-coated liposomes with a surplus amount of liposomes.

~~21.~~15. The method of claim ~~20~~14, wherein the lipid mixture comprises the cationic lipid and the organic solvent at a ratio of about 40 mg cationic lipid per mL organic solvent to about 60 mg cationic lipid per mL organic solvent, optionally, at a ratio of about 50 mg cationic lipid per mL organic solvent.

~~22.~~16. The method of claim ~~20~~-14 or claim ~~21~~15, wherein the process of making liposomes further comprises rehydrating the lipid mixture with a rehydration solution to form a rehydrated lipid mixture and then agitating, resting, and sizing the rehydrated lipid mixture.

~~23. The method of claim 22, wherein sizing the rehydrated lipid mixture comprises sonicating, extruding and/or filtering the rehydrated lipid mixture.~~

~~24. The method of any one of claims 20-23, comprising the steps of Example 1.~~

~~25. The method of any one of claims 20-24, wherein the nanoparticle has a zeta potential of about 40 mV to about 60 mV, optionally, about 45 mV to about 55 mV.~~

~~26. The method of any one of claims 20-25, wherein the core of the nanoparticle comprises less than about 0.5 wt% nucleic acid and/or the core comprises a cationic lipid bilayer~~

~~27. The method of any one of claims 20-27, wherein the outermost layer of the nanoparticle comprises a cationic lipid bilayer and/or the surface of the nanoparticle comprises a plurality of hydrophilic moieties of the cationic lipid of the cationic lipid bilayer.~~

~~28.~~17. The method of any one of claims ~~20~~14-~~27~~16, wherein the mRNAs encode a SARS-CoV-2 Spike (S) protein or a fragment thereof.

~~29.~~18. The method of claim ~~28~~17, wherein the S protein comprises the amino acid sequence set forth in Figure 20.

~~30.~~19. The method of any one of the claims ~~20~~14-~~29~~18, wherein the mRNAs encode a SARS-CoV-2 membrane protein, envelope protein, or a nucleocapsid protein.

~~31. A nanoparticle made by the method of any one of claims 20-30.~~

~~32.~~20. A cell comprising a nanoparticle as described in any one of claims 1-~~19~~ 13~~or according to claim 31~~.

~~33.~~21. The cell of claim ~~32~~20, which is an antigen presenting cell (APC), optionally, a dendritic cell (DC).

~~34. A population of cells, wherein at least 50% of the population are cells according to claim 32 or claim 33.~~

~~35.~~22. A pharmaceutical composition comprising a plurality of nanoparticles according to any one of claims 1~~-19~~ 13 ~~or claim 31~~ and a pharmaceutically acceptable carrier, diluent, or excipient.

~~36.~~23. The pharmaceutical composition of claim ~~35~~22, wherein the composition comprises about 10^{10} nanoparticles per mL to about 10^{15} nanoparticles per mL, optionally about 10^{12} nanoparticles ± 10% per mL.

24. Use of the pharmaceutical composition of claim 22 or claim 23 in the manufacture of a medicament for preventing SARS-CoV-2 infection in a subject, wherein the medicament induces an immune response against SAR-CoV-2 in a subject, and wherein the medicament is to be administered to a subject.

~~37.~~25. Use of ~~A method of inducing an immune response against a SARS-CoV-2 virus in a subject, the method comprising administering to the subject~~ the pharmaceutical composition of claim ~~35~~ 22 or claim ~~36~~23 in the manufacture of a medicament for inducing an immune response against a SARS-CoV-2 virus in a subject, wherein the medicament is to be administered to a subject.

~~38. The method of claim 37, wherein the nucleic acid molecules are mRNA.~~

~~39. The method of claim 37 or claim 38, wherein the composition is systemically administered to the subject.~~

~~40. The method of claim 39, wherein the composition is administered intravenously.~~

~~41. The method of any one of claims 37-40, wherein the pharmaceutical composition is administered in an amount which is effective to activate dendritic cells (DCs) in the subject.~~

~~42. The method of any one of claims 37-41, wherein the immune response is a T cell-mediated immune response.~~

~~43. The method of any one of claims 37-42, wherein the immune response is a humoral immune response.~~

~~44. The method of claim 43, wherein the immune response comprises production of antibodies to a SARS CoV-2 protein.~~

~~45.~~26. The ~~method~~ use of ~~any one of claims 37-43~~claims 24 or 25, wherein a single dose of the composition comprises about 0.00050 mg/kg to about 1.5 mg/kg of nucleic acid.

~~46.~~27. The use ~~method~~ of claim ~~45~~26, wherein the nucleic acid is encapsulated into about 0.008 mg/kg to about 1.5 mg/kg of liposome material.

~~47.~~28. The use ~~method~~ of claim ~~45~~ 26 or claim ~~46,~~ 27, wherein a single dose of composition comprises about 0.000625 mg/kg to about 0.08 mg/kg nucleic acid.

~~48.~~29. The use ~~method~~ of claim ~~47~~28, wherein a single dose of composition comprises about 0.000625 mg/kg of mRNA, about 0.00125 mg/kg mRNA, about 0.0025 mg/kg mRNA, about 0.005

mg/kg mRNA, about 0.01 mg/kg mRNA, about 0.02 mg/kg mRNA, about 0.04 mg/kg mRNA, or about 0.08 mg/kg mRNA.

~~49.~~30. The use ~~method~~ of any one of claims ~~37-48~~24-29, ~~comprising administering to the subject~~wherein multiple doses of pharmaceutical composition is to be administered to a subject over a treatment period of about 18 months.

~~50.~~31. The use ~~method~~ of claim ~~49~~30, ~~comprising administering~~wherein (a) an initial set of doses of the pharmaceutical composition is to be administered to a subject, and wherein each administration is separated by two weeks, followed by (b) a subsequent set of doses of pharmaceutical composition~~,~~ wherein each is to be administered once per month.

~~51.~~32. The use ~~method~~ of claim ~~50~~31, wherein the initial set of three doses are to be administered over an initial treatment period of about four weeks, and the subsequent set of doses are to be administered over a subsequent treatment period of about 12 months.